Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.64 |
| ▸ | EML4 | Q9HC35 | 6/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.54 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | TTK | P33981 | 2/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127610 | 0.93 | ALK (0.56) | ALKEML4CCNA2CDK2PLK1 | |
| SCHEMBL328290 | 0.93 | ALK (0.76) | ALKEML4CDK2PLK1RET | |
| SCHEMBL17689760 | 0.89 | EML4 (0.51) | ALKEML4RETROS1FLT3 | |
| SCHEMBL16206813 | 0.88 | EML4 (0.51) | ALKEML4RETROS1FLT3 | |
| SCHEMBL10126754 | 0.86 | ALK (0.65) | ALKEML4CDK2RETROS1 | |
| SCHEMBL10129226 | 0.84 | EML4 (0.88) | ALKEML4CDK2RETROS1 | |
| SCHEMBL10126771 | 0.83 | ALK (0.63) | ALKEML4CDK2RETROS1 | |
| SCHEMBL10157683 | 0.83 | ALK (0.77) | ALKEML4CDK2RETROS1 | |
| SCHEMBL10127376 | 0.83 | EML4 (0.67) | ALKEML4RETROS1FLT3 | |
| SCHEMBL10127532 | 0.83 | EGFR (0.54) | ALKEML4RETROS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALK 2/4885EML4 1/4885CCNA2 3352/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALK 2/4885EML4 1/4885CCNA2 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.